RCEL · Avita Medical

The thesis

AVITA Medical's shares are modestly more likely than not to beat the S&P 500 over the next three months. Third-quarter results on 5 November 2026 showed faster growth, a higher 2026 revenue guide and cash use close to zero. The fourth-quarter report, expected in late February 2027, settles whether the promised cash-flow breakeven arrives on implied revenue of $24.9–26.9 million.

Brokers kept raising their numbers through the week after the report. TD Cowen raised its target to $22 on 12 November 2026, according to analyst-action news. Benzinga reported BTIG at $21 (from $15) on 6 November 2026 and Lake Street at $20 on 7 November 2026. In Australia, Morgans moved to Hold from Sell and raised its target to A$5.00 from A$2.20, and Canaccord Genuity raised its target to A$5.92 from A$4.74, according to FNArena's broker log dated 9 November 2026. Bell Potter raised its target to A$6.30 on 10 November 2026.

The price already reflects much of this. The shares closed at $16.20 on 12 November 2026, up 106.4% over three months, and sit below all three US targets of $20 to $22. The rating is Medium because the results and the target raises support the case, while the size of the rally, $60 million of costly debt and a thin cash cushion limit the odds.

Bullish and bearish views on Avita Medical, Inc.

The bull case on Avita Medical, Inc. (RCEL), in brief: revenue growth sharply accelerated. The bear case: fourth-quarter breakeven is still a promise.

Bull case

• Revenue growth sharply accelerated. Third-quarter revenue rose 53% from a year earlier to $26.11 million, against $17.06 million a year before, according to the Form 10-Q filed 5 November 2026. Sequential growth went from about 10% in the first quarter to 13% in the second and 20% in the third, according to Earnings Whispers on 5 November 2026.
• The core device is driving it. US revenue from RECELL, the company's spray-on skin-cell device, was $22.4 million in the third quarter, up from $18.5 million in the second, on 3,196 units, according to Earnings Whispers' 5 November 2026 summary of the results.
• Guidance beat analyst estimates. On 5 November 2026 the company raised 2026 revenue guidance to $92–94 million from $86–89 million, against an $86.85 million estimate cited by Benzinga. The implied fourth quarter of $24.9–26.9 million compared with a $23.8 million estimate.
• Cash use nearly reached zero. Net cash use was about $0.6 million in the third quarter, down from $3.2 million in the second, according to the 5 November 2026 release. Management reaffirmed fourth-quarter cash-flow breakeven, and the operating loss narrowed to $2.6 million from $9.2 million a year earlier.
• Going-concern doubt was removed. Management said on 5 November 2026 that substantial doubt about the company's ability to continue had been resolved, and the qualification was dropped from the third-quarter Form 10-Q.
• Medicare payment is now final. The Centers for Medicare & Medicaid Services (CMS) finalized national physician payment values and simpler billing codes for RECELL procedures, effective 1 January 2027, according to the company's 5 November 2026 announcement.
• Margins expanded with volume. Gross margin was 84.0% in the third quarter, up from 81.9% in the second, according to the 5 November 2026 release.
• Even the sceptic moved up. Morgans, which had rated the Australian-listed shares Sell with an A$2.20 target, upgraded to Hold with A$5.00 after the results, citing 53% growth, flat operating expenses and lower cash outflows, per FNArena on 9 November 2026.

Bear case

• Fourth-quarter breakeven is still a promise. Third-quarter net cash use of about $0.6 million was close to breakeven but not at it, according to the 5 November 2026 release. Management also flagged seasonally higher cash use in the first quarter of 2027 from incentive pay and benefits, per Earnings Whispers on 5 November 2026.
• Part of the third quarter was seasonal. Management attributed about $1 million of third-quarter revenue to summer burn seasonality, per Earnings Whispers on 5 November 2026. The fourth-quarter guide of $24.9–26.9 million brackets the $26.1 million third quarter, so the company's own range allows a sequential decline.
• The loan is costly and has covenants. The January 2026 Perceptive credit agreement charges the higher of the Secured Overnight Financing Rate (SOFR) or 4.00%, plus 7.50%, according to the 13 January 2026 Form 8-K. It requires at least $5 million of unrestricted cash and a minimum trailing-twelve-month revenue level. Cash was $10.5 million on 30 September 2026, against $60 million of borrowings after the final $10 million draw.
• The lender's warrant added shares. Perceptive received 387,716 shares from a cashless warrant exercise, according to company news on 3 November 2026. The company counted 31,420,219 shares outstanding on 2 November 2026.
• The rally already discounts the beat. The shares rose 106.4% in three months, from $7.85 on 14 August 2026 to $16.20 on 12 November 2026. They fell 6.4% in the 12 November 2026 session alone, from $17.30, a reminder that a rise of this size on a small share count can reverse quickly.

Price setup

The shares closed at $16.20 on 12 November 2026, after $17.65 on 10 November 2026 and $17.30 on 11 November 2026. The 52-week intraday high is $18.43, set on 9 November 2026; the last close is 12.1% below it. The close before the after-market report was $15.68 on 5 November 2026, so the shares still hold part of the post-earnings gain.

As of 12 November 2026 the 50-day moving average was $13.31 and the 200-day moving average $7.10, both well under the price. The 52-week closing low was $3.27 on 17 December 2025. The $15.68 pre-report close is the nearest level at which the shares would give back the whole post-earnings gain. A close under the 50-day average would erase most of the autumn rally.

Catalysts ahead

• ~30 November 2026 (est.): Full six-month Cohealyx clinical dataset, expected in November 2026; no day announced. Shows whether Cohealyx, at $2.1M of Q3 2026 revenue, has the clinical data to become a second growth line beside RECELL.
• 1 January 2027: New RECELL billing codes and national Medicare physician payment values take effect. First-quarter 2027 revenue becomes the first to show whether the finalized CMS framework lifts RECELL procedure volume.
• ~25 February 2027 (est.): Q4 2026 results; the company has not announced the date. Shows whether cash-flow breakeven arrived and whether revenue landed in the implied $24.9–26.9M range.

What would change the view

A weekly close below $9.00, which would return the shares to the lower part of the range traded since the 7 August 2026 post-earnings jump. A cut to the $92–94 million 2026 revenue guidance or a later date for fourth-quarter cash-flow breakeven also breaks the case.

The risks this note tracks, each with what would confirm it:

• The guided Q4 2026 cash-flow breakeven slips into 2027. Confirmed by: Q4 net cash use above the $0.6M Q3 level, or management giving a later breakeven date at or before the fourth-quarter report.
• Third-quarter revenue included about $1M of seasonal strength, so growth stalls from the $26.1M level. Confirmed by: Q4 2026 revenue below $24.9M, or a cut to the $92–94M full-year guidance.
• $60M of costly borrowings against $10.5M of cash at 30 September 2026, with a $5M minimum cash covenant, leaves a share sale into strength possible. Confirmed by: a prospectus supplement or 8-K announcing a registered offering or at-the-market share sales.
• The 106.4% three-month advance unwinds even on strong results. Confirmed by: a close back under the $15.68 pre-report close of 5 November 2026, or TD Cowen, BTIG or Lake Street cutting its target below the share price.
• The finalized CMS payment values fail to lift RECELL procedure volume after 1 January 2027. Confirmed by: RECELL US revenue falling from the $22.4M Q3 2026 level in first-quarter 2027 results, with management citing physician payment.

What it trades with

AVITA Medical trades on company-specific news: its quarterly reports, Medicare reimbursement decisions and its financing. Its moves have little to do with the broad medical-device group. With about 31.4 million shares outstanding on 2 November 2026, the stock has made single-session moves above 50%, as on 7 August 2026, which makes it more sensitive to news than to index direction. Its securities also trade on the Australian Securities Exchange under the code AVH, so Australian trading and Australian broker calls, such as the Morgans upgrade, can move the price before the US open.